PACTR202007606032743Recruiting未知
ebulized heparin in patients with mainly moderate coronavirus disease 2019: Randomized controlled trial. COVID-19
Dr Tarek Ismail0 sites100 target enrollmentStarted: June 19, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 19 Year(s) to 44 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Age:18-60 years old, recently diagnosed (within 24 h) and moderate symptoms of the disease ongoing SARS-CoV-2 infection confirmed in upper or lower respiratory tract specimens with real time reverse transcriptase polymerase chain reaction (RT-PCR), willingness to participate. Pneumonia on computed tomography of the chest will not be mandatory for inclusion.
Exclusion Criteria
- •age below 18 years, severe conditions including malignancies, heart, liver, or kidney disease, poorly controlled metabolic diseases, pregnancy or lactation, severe hepatic impairment (e.g. Child Pugh grade C, alanine aminotransferase more than fivefold the upper limit), severe renal impairment (estimated glomerular filtration rate =30 mL/min/1.73 m2) , receipt of continuous renal replacement therapy, hemodialysis, peritoneal dialysis, allergy to heparin (including any history of heparin-induced thrombocytopenia), pulmonary hemorrhage in the previous 3 months, uncontrolled bleeding or a significant bleeding disorder, an intracranial hemorrhage in the past 12 months and patients with mild and severe COVID-19 will be excluded.
Investigators
Similar Trials
Completed
Not Applicable
Effectiveness of low-molecular-weight heparin for prevention of deep venous thrombosis after surgery for colorectal cancer in Japanese patients: a randomized controlled phase III trialcolorectal cancerJPRN-UMIN000030582Tokyo Metropolitan Hiroo Hospital160
Completed
Phase 4
Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two dosespulmonary embolismNL-OMON55412Academisch Medisch Centrum200
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womeEUCTR2012-001505-24-IEThe Rotunda Maternity Hospital850
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 18.0Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855EUCTR2012-001505-24-BEAcademic Medical Center850
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womeEUCTR2012-001505-24-NLAcademic Medical Center790